following an abbreviated submission:
futibatinib (Lytgobi®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with locally
advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2
(FGFR2) fusion or rearrangement that have progressed after at least one prior line of
systemic therapy.
Futibatinib offers an additional treatment choice in the therapeutic class of fibroblast
growth factor receptor (FGFR) tyrosine kinase inhibitors.
Another FGFR tyrosine kinase inhibitor was accepted for use under the end of life and
orphan process.
This advice applies only in the context of approved NHSScotland Patient Access Scheme
(PAS) arrangements delivering the cost-effectiveness results upon which the decision was
based, or PAS/ list prices that are equivalent or lower.
Download detailed advice270KB (PDF)
Medicine details
- Medicine name:
- futibatinib (Lytgobi)
- SMC ID:
- SMC2661
- Indication:
For treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
- Pharmaceutical company
- Taiho Oncology
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 April 2025